Why Is HeartBeam (BEAT) Stock Up +67.56% Today?
Key Takeaways
- BEAT shares surged roughly 67.6% Monday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its at-home heart attack assessment technology.
- The designation covers the company's 3D ECG platform as a tool to help physicians assess a possible heart attack when symptoms begin, wherever the patient is.
- Breakthrough status provides prioritized FDA review and is a prerequisite for certain expedited Medicare coverage pathways.
- The stock ran as high as roughly 90% intraday before pulling back, reflecting heavy speculative volume in a low-priced, high-volatility name.
- Broader markets were mildly higher, but the move was overwhelmingly company-specific rather than sector-driven.
- Traders are now watching for FDA alignment on a pivotal study design and upcoming clinical data at the TCT conference.
Opening Summary
HeartBeam, Inc. (BEAT), a Santa Clara, California-based medical technology company developing cable-free, 3D electrocardiogram (ECG) devices for cardiac monitoring outside traditional medical settings, saw its stock rocket higher on Monday after the FDA granted Breakthrough Device Designation to its HeartBeam System for assessing potential heart attacks at home. The shares climbed from a prior close of $0.4346 to around $0.73 in midday trading, a gain of approximately 67.56%, after earlier spiking as much as 90% at the session's peak. The move was driven squarely by the regulatory news, which markets read as a de-risking event for the company's flagship heart attack detection program.
FDA Breakthrough Device Designation
The primary catalyst behind the stock's surge was the FDA's decision to grant Breakthrough Device Designation to the HeartBeam System for at-home heart attack (myocardial infarction) assessment. The designation recognizes the potential of HeartBeam's 3D ECG technology, which captures the heart's electrical signals from three non-coplanar dimensions and synthesizes them into a 12-lead ECG, enabling physicians to evaluate signs of a possible heart attack when symptoms first appear rather than only after a patient reaches a hospital or clinic.
The FDA granted the designation within 30 days of HeartBeam's request, well ahead of the agency's 60-day statutory review period—a signal investors interpreted as strong regulatory receptivity to the technology. Crucially, the company is building the heart attack capability on the same 3D ECG platform behind its already FDA-cleared arrhythmia product, and it does not currently anticipate needing new hardware development.
Medicare Coverage Implications
Beyond faster regulatory interaction, the designation carries commercial significance. Breakthrough Device Designation is a prerequisite for certain expedited Medicare coverage mechanisms, including the proposed Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, under which the Centers for Medicare and Medicaid Services could issue a proposed national coverage determination the same day an eligible device receives FDA clearance. HeartBeam has also requested enrollment in the FDA's Total Product Life Cycle Advisory Program. The company estimates the heart attack assessment market at roughly $15 billion within a broader cardiac platform opportunity of more than $40 billion, figures that fueled the bullish repricing of the stock.
Market Context and Trading Activity
The move unfolded on dramatically elevated volume, consistent with a news-driven breakout in a low-priced, thinly traded stock. Trading activity was far above the stock's recent daily averages, with single-minute volume figures exceeding levels seen across full sessions in prior weeks. The catalyst-driven surge also pushed the shares well through prior resistance and their short-term moving averages, reflecting a classic gap-and-run technical move.
Broader equity indices traded modestly higher, but the gains were too small to explain the outsized rally in BEAT. The price action was overwhelmingly company-specific, driven by the regulatory milestone and the market's reassessment of the company's addressable opportunity rather than by sector or macro momentum.
What Comes Next for BEAT
Looking ahead, the nearest catalysts are clinical and regulatory. HeartBeam expects to seek FDA alignment on the design of a multicenter pivotal study in the coming months, with patient enrollment anticipated shortly thereafter. Nearer term, the company plans to provide updates on its ALIGN-ACS pilot data at the TCT conference and on the HEADSTART-ACS study in the coming weeks.
Investors should note that Breakthrough Device Designation is not the same as FDA clearance and does not establish that the technology is safe or effective for commercial use. The stock's sharp repricing also leaves BEAT vulnerable to volatility, particularly given the company's early commercial stage, ongoing net losses, and the financing and dilution considerations typical of pre-revenue medical device developers. Sustained gains will ultimately depend on pivotal trial execution, regulatory clearance, and reimbursement outcomes.
Trending AI Robots
For traders seeking a more systematic approach to market moves like this one, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI trading bots. Tickeron provides hundreds of AI-powered trading bots covering thousands of tickers, but only those demonstrating the strongest performance under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots page to discover which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
BEAT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BEAT turned positive on October 01, 2026. Looking at past instances where BEAT's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 69 cases where BEAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on BEAT as a result. In 68 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
BEAT moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +56.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAT advanced for three days, in 168 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BEAT broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BEAT entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.571) is normal, around the industry mean (7.432). BEAT's P/E Ratio (149.254) is considerably higher than the industry average of (46.656). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a wireless medical technology company, which focuses on the delivery of health information
Industry ServicestotheHealthIndustry
Advertisement